Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.63 |
| ▸ | BCL2 | P10415 | 1/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163971 | 0.93 | ACLY (0.66) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184867 | 0.92 | ACLY (0.62) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184499 | 0.89 | ACLY (0.78) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184069 | 0.89 | ACLY (0.59) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184278 | 0.87 | ACLY (0.61) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184106 | 0.87 | ACLY (0.61) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184619 | 0.87 | ACLY (0.56) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184851 | 0.86 | ACLY (0.54) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL184924 | 0.85 | ACLY (0.63) | ACLYBCL2CXCR3NR1H2NR1H3 | |
| SCHEMBL15164062 | 0.84 | ACLY (0.88) | ACLYBCL2CXCR3NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | ACLY 4026/4885BCL2 1/4885CXCR3 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.